Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX‐02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers

Abstract

ELX‐02 is an investigational synthetic eukaryotic ribosome–selective glycoside optimized as a translational read‐through molecule that induces read through of nonsense mutations, resulting in normally localized full‐length functional proteins. ELX‐02 is being developed as a therapy for genetic diseases caused by nonsense mutations. Two phase 1a, randomized, double‐blind placebo‐controlled, single‐ascending‐dose studies were conducted in healthy human subjects to evaluate the safety and pharmacokinetics of ELX‐02. Single subcutaneously injected doses of ELX‐02 between 0.3 mg/kg and 7.5 mg/kg showed an acceptable safety profile without severe or serious drug‐related adverse events, including a lack of renal and ototoxicity events. Injection of ELX‐02 resulted in a rapid time to peak concentration and elimination phase, with complete elimination from the vascular compartment within 10 hours. ELX‐02 area under the concentration‐time curve to infinity showed dose‐exposure linearity (24‐fold increase for a 25‐fold dose increase), and the maximum concentration showed dose proportionality (17‐fold increase for a 25‐fold increase). The mean apparent volume of distribution was dose dependent, suggesting an increased distribution and tissue uptake of ELX‐02 at higher doses. The primary route of excretion was in the urine, with the majority of the compound excreted unchanged. These results support the evaluation of the safety, pharmacokinetics, and efficacy of repeat dosing in future studies.

CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine

“…Moreover, ELX-02 was less cytotoxic than gentamicin in a model for ototoxicity (Xue et al, 2014). In phase I clinical trials with healthy volunteers, ELX-02 was well tolerated and exhibited a favorable safety profile, although mild side effects were also reported (Leubitz et al, 2019). Early-stage clinical trials are in progress to evaluate the effects of multiple dose escalation of ELX-02 in CF patients carrying the G542X mutation in at least one allele (NCT04126473, NCT04135495).…”

Cystic fibrosis in the year 2020: A disease with a new face

“…Read through drugs that overread premature stop codons are under development for subjects with a stop codon mutation. After the negative results for ataluren, which was the first read through drug that was tested clinically in CF, there is now the novel compound ELX‐02 that shows promise in preclinical assays . A CFTR amplifier is a CFTR modulator that is not mutation or mutation class specific.…”

FDA orphan drug designations for lysosomal storage disorders – a cross-sectional analysis

“…Targeting the affected gene: Stop-codon read through in missense mutations [36] 6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-Ltalofuranosyl)-paromamine sulfate…”